Patent EP0016593A1 successfully refreshed from Google Patents.
EP0351173A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Substance having anti-retrovirus activity
Assignee: Osaka Prefectural Government
•
Filing: 1989-07-10
•
Granted: —
•
Expires: 2009-07-10
Abstract
Abstract A reaction product of Amphotericin B with a sulfonating agent, having an excellent anti-retrovirus activity, especially an excellent HIV proliferation inhibitory activity. The substance of the present invention can be used for prevention and/or treatment of a retrovirus infection diseases such as AIDS.
Inventors
- 👤 Toru Otake
- 👤 Haruyo Mori
- 👤 Noboru Ueba
- 👤 Keiichi Miyano
- 👤 Kazuo Matsumoto
- 👤 Tamon Moriya
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-03 22:05
CPC Classifications
C; C07; C07H; C07H17/00; C07H17/04; C07H17/08; A; A61; A61P; A61P31/00; A61P31/12
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
16 words
A reaction product of Amphotericin B with a sulfonating agent, or a pharmaceutically acceptable salt thereof.
Claim 2
Dependent Claim
16 words
A reaction product of Amphotericin B with a sulfonating agent, or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
11 words
The reaction product of claim 1 which has an anti-retrovirus activity.
Claim 4
Dependent Claim
12 words
The reaction product of claim 1 which has an HIV proliferation-inhibitory activity.
Claim 5
Dependent Claim
67 words
The reaction product of claim 1 which has the following physicochemical properties: (1) IR absorption spectra by KBr tablet method: Absorption band at around 3450-3420, 1630, 1240, 1120-1110 and 620 cm⁻¹ (2) Ratio of carbon, nitrogen and sulfur atoms: C : N : S = 21-22 : 1 : 3-4 (3) Solubility: Highly soluble in water, hardly soluble in ethanol, and insoluble in ethyl acetate and ether.
Claim 6
Dependent Claim
74 words
The reaction product of claim 1 which has the following physicochemical properties: (1) IR absorption spectra by KBr tablet method: Absorption band at around 3450, 1630, 1240, 1120 and 620 cm⁻¹. (2) High performance liquid chromatogram: [conditions; stationary phase: octadecanylated silica-gel, 15 cm x 4.6 mmφ, mobile phase: methanol : water = 40 : 60, column temperature: 25°C, detector: UV 254 nm, flow rate: 0.5 ml/min.] Retention time of main peak: around 1.9 minutes.
Claim 7
Dependent Claim
74 words
The reaction product of claim 1 which has the following physicochemical properties: (1) IR absorption spectra by KBr tablet method: Absorption band at around 3420, 1630, 1240, 1110 and 620 cm⁻¹. (2) High performance liquid chromatogram: [conditions; stationary phase: octadecanylated silica-gel, 15 cm x 4.6 mmφ, mobile phase: methanol : water = 40 : 60, column temperature: 25°C, detector: UV 254 nm, flow rate: 0.5 ml/min.] Retention time of main peak: around 1.8 minutes.
Claim 8
Dependent Claim
32 words
A pharmaceutical composition which comprises a therapeutically effective amount of a reaction product of Amphotericin B with a sulfonating agent, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier therefor.
Claim 9
Dependent Claim
32 words
A pharmaceutical composition which comprises a therapeutically effective amount of a reaction product of Amphotericin B with a sulfonating agent, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier therefor.
Claim 10
Dependent Claim
25 words
An anti-retrovirus agent comprising a reaction product of Amphotericin B with a sulfonating agent, or a pharmaceutically acceptable salt thereof as an active therapeutic substance.
Claim 11
Dependent Claim
25 words
An anti-retrovirus agent comprising a reaction product of Amphotericin B with a sulfonating agent, or a pharmaceutically acceptable salt thereof as an active therapeutic substance.
Claim 12
Dependent Claim
25 words
The use of the agent of claim 8 for the manufacture of a medicament for the therapeutic treatment of the acquired immune deficiency syndrome (AIDS).
Claim 13
Dependent Claim
25 words
The use of the agent of claim 8 for the manufacture of a medicament for the therapeutic treatment of the human immunodeficiency virus (HIV) infection.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.